Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Kunavisarut, Tada ^a,e   Kak, Ipshita ^a   MacMillan, Christina ^b   Ralhan, Ranju ^a,b,d   Walfish, Paul G ^a,b,c,d  

^a MOUNT SINAI HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Aggressiveness; Ep ICD; EpCAM; EpEx; ESLI; Metastatic; Papillary thyroid Microcarcinoma

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; EXTRACELLULAR DOMAIN EPITHELIAL CELL ADHESION MOLECULE; INTRACELLULAR DOMAIN EPITHELIAL CELL ADHESION MOLECULE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CELL MEMBRANE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACELLULAR DOMAIN EPITHELIAL CELL ADHESION MOLECULE SUBCELLULAR LOCALIZATION INDEX; LYMPH NODE METASTASIS; MALE; ONCOLOGICAL PARAMETERS; PAPILLARY THYROID MICROCARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TUMOR VOLUME;

ADULT; AGED; ANTIGENS, NEOPLASM; BINDING SITES; CARCINOMA, PAPILLARY; CELL ADHESION MOLECULES; CELL NUCLEUS; CYTOPLASM; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SENSITIVITY AND SPECIFICITY; THYROID GLAND; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84868679076     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-523     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
2. Sherman SI. Thyroid carcinoma. Lancet 2003, 361(9356):501-511. 10.1016/S0140-6736(03)12488-9, 12583960.
3. Hughes DT, Haymart MR, Miller BS, Gauger PG, Doherty GM. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid 2011, 21(3):231-236. 10.1089/thy.2010.0137, 21268762.
4. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006, 295(18):2164-2167. 10.1001/jama.295.18.2164, 16684987.
5. Hedinger CYR, Sobin L. Histologic typing of thyroid tumors 1988, Springer-Verlag.
6. Wang C, Crapo LM. The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am 1997, 26(1):189-218. 10.1016/S0889-8529(05)70240-1, 9074859.
7. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer 1985, 56(3):531-538. 10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3, 2408737.
8. Bruno R, Giannasio P, Chiarella R, Capula C, Russo D, Filetti S, Costante G. Identification of a neck lump as a lymph node metastasis from an occult contralateral papillary microcarcinoma of the thyroid: key role of thyroglobulin assay in the fine-needle aspirate. Thyroid 2009, 19(5):531-533. 10.1089/thy.2009.0049, 19416000.
9. Xu YH, Song HJ, Qiu ZL, Luo QY. Brain metastases with exceptional features from papillary thyroid carcinoma: report of three cases. Hell J Nucl Med 2011, 14(1):56-59.
10. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer 2003, 98(1):31-40. 10.1002/cncr.11442, 12833452.
11. Roti E, degli Uberti EC, Bondanelli M, Braverman LE. Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol 2008, 159(6):659-673. 10.1530/EJE-07-0896, 18713843.
12. Kucuk NO, Tari P, Tokmak E, Aras G. Treatment for microcarcinoma of the thyroid-clinical experience. Clin Nucl Med 2007, 32(4):279-281. 10.1097/01.rlu.0000257272.90126.3d, 17413573.
13. Ito Y, Miyauchi A. A therapeutic strategy for incidentally detected papillary microcarcinoma of the thyroid. Nat Clin Pract Endocrinol Metab 2007, 3(3):240-248. 10.1038/ncpendmet0428, 17315032.
14. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, Ladenson PW, Magner J, et al. Recurrence after treatment of micropapillary thyroid cancer. Thyroid 2009, 19(10):1043-1048. 10.1089/thy.2008.0407, 19772419.
15. Bernet V. Approach to the patient with incidental papillary microcarcinoma. J Clin Endocrinol Metab 2010, 95(8):3586-3592. 10.1210/jc.2010-0698, 20685885.
16. Sugitani I, Toda K, Yamada K, Yamamoto N, Ikenaga M, Fujimoto Y. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 2010, 34(6):1222-1231. 10.1007/s00268-009-0359-x, 20066418.
17. Haymart MR, Cayo M, Chen H. Papillary thyroid microcarcinomas: big decisions for a small tumor. Ann Surg Oncol 2009, 16(11):3132-3139. 10.1245/s10434-009-0647-6, 19653044.
18. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A. Papillary microcarcinoma of the thyroid: how should it be treated?. World J Surg 2004, 28(11):1115-1121. 10.1007/s00268-004-7644-5, 15490053.
19. Buffet C, Golmard JL, Hoang C, Tresallet C, Du Pasquier Fediaevsky L, Fierrard H, Aurengo A, Menegaux F, Leenhardt L. Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. Eur J Endocrinol 2012, 167(2):267-275.
20. Ugolini C, Giannini R, Lupi C, Salvatore G, Miccoli P, Proietti A, Elisei R, Santoro M, Basolo F. Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 2007, 17(5):381-388. 10.1089/thy.2006.0305, 17542667.
21. Khoo ML, Ezzat S, Freeman JL, Asa SL. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab 2002, 87(4):1810-1813. 10.1210/jc.87.4.1810, 11932322.
22. Min HS, Choe G, Kim SW, Park YJ, Parkdo J, Youn YK, Park SH, Cho BY, Park SY. S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid. Mod Pathol 2008, 21(6):748-755. 10.1038/modpathol.2008.51, 18360353.
23. Kim HY, Park WY, Lee KE, Park WS, Chung YS, Cho SJ, Youn YK. Comparative analysis of gene expression profiles of papillary thyroid microcarcinoma and papillary thyroid carcinoma. J Cancer Res Ther 2010, 6(4):452-457. 10.4103/0973-1482.77103, 21358079.
24. Nucera C, Pontecorvi A. Clinical outcome, role of BRAFV600E, and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer?. Frontiers in endocrinology 2012, 3(33):1-5. 3355937, 22649402.
25. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 2010, 31(11):1913-1921. 10.1093/carcin/bgq187, 20837599.
26. Ralhan R, He HC, So AK, Tripathi SC, Kumar M, Hasan MR, Kaur J, Kashat L, MacMillan C, Chauhan SS, et al. Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers. PLoS One 2010, 5(11):e14130. 10.1371/journal.pone.0014130, 2994724, 21152431.
27. Ralhan R, Cao J, Lim T, Macmillan C, Freeman JL, Walfish PG. EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis. BMC Cancer 2010, 10:331. 10.1186/1471-2407-10-331, 2912862, 20579375.
28. He HCH, Kashat L, Kak I, Kunavisarut T, Gundelach R, Kim D, So AKC, MacMillan C, Freeman JL, Ralhan R, et al. An Ep-ICD Based Index Is a Marker of Aggressiveness and Poor Prognosis in Thyroid Carcinoma. PLoS One 2012, 7(9):e42893. 10.1371/journal.pone.0042893, 3458098, 23049733.
29. Kasai N, Sakamoto A. New subgrouping of small thyroid carcinomas. Cancer 1987, 60(8):1767-1770. 10.1002/1097-0142(19871015)60:8<1767::AID-CNCR2820600816>3.0.CO;2-P, 3652005.
30. Edge SB, et al. AJCC cancer staging manual 2010, New York: Springer, Edge SB, 7.
31. Zhang L, Wei WJ, Ji QH, Zhu YX, Wang ZY, Wang Y, Huang CP, Shen Q, Li DS, Wu Y. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab 2012, 97(4):1250-1257. 10.1210/jc.2011-1546, 22319042.
32. Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009, 69(14):5627-5629. 10.1158/0008-5472.CAN-09-0654, 19584271.
33. Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L, Zlobec I. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010, 103(3):382-390. 10.1038/sj.bjc.6605762, 2920016, 20606680.